Vanguard Group’s Taysha Gene Therapies TSHA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
$73M Buy
13,267,805
+418,192
+3% +$2.03M ﹤0.01% 1990
2025
Q3
$42M Buy
12,849,613
+1,955,486
+18% +$5.54M ﹤0.01% 2248
2025
Q2
$25.2M Buy
10,894,127
+2,123,206
+24% +$4.61M ﹤0.01% 2458
2025
Q1
$12.2M Sell
8,770,921
-135,843
-2% -$227K ﹤0.01% 2740
2024
Q4
$15.4M Buy
8,906,764
+641,305
+8% +$1.33M ﹤0.01% 2721
2024
Q3
$16.6M Buy
8,265,459
+1,098,122
+15% +$2.41M ﹤0.01% 2682
2024
Q2
$16.1M Buy
7,167,337
+1,249,923
+21% +$3.64M ﹤0.01% 2672
2024
Q1
$17M Sell
5,917,414
-278,153
-4% -$580K ﹤0.01% 2680
2023
Q4
$11M Buy
6,195,567
+867,703
+16% +$1.73M ﹤0.01% 2896
2023
Q3
$16.8M Buy
5,327,864
+3,738,616
+235% +$6.98M ﹤0.01% 2614
2023
Q2
$1.05M Buy
1,589,248
+5,810
+0.4% +$4.21K ﹤0.01% 3881
2023
Q1
$1.26M Buy
1,583,438
+27,772
+2% +$35.9K ﹤0.01% 3847
2022
Q4
$3.52M Buy
1,555,666
+484,864
+45% +$982K ﹤0.01% 3454
2022
Q3
$2.07M Hold
1,070,802
﹤0.01% 3728
2022
Q2
$3.98M Buy
1,070,802
+58,638
+6% +$233K ﹤0.01% 3497
2022
Q1
$6.6M Buy
1,012,164
+128,517
+15% +$961K ﹤0.01% 3377
2021
Q4
$10.3M Buy
883,647
+77,929
+10% +$1.18M ﹤0.01% 3186
2021
Q3
$15M Buy
805,718
+177,074
+28% +$3.37M ﹤0.01% 3014
2021
Q2
$13.3M Buy
628,644
+168,396
+37% +$3.88M ﹤0.01% 3056
2021
Q1
$9.34M Sell
460,248
-4,602
-1% -$125K ﹤0.01% 3183
2020
Q4
$12.3M Buy
464,850
+389,850
+520% +$8.4M ﹤0.01% 2884
2020
Q3
$1.68M Buy
+75,000
New +$1.76M ﹤0.01% 3534

Other funds holding TSHA